FDA expands indications for SculpSure

October 18, 2017

The U.S. Food and Drug Administration granted an expanded FDA 510(k) clearance in September for Cynosure’s non-invasive body contouring product, SculpSure.

The U.S. Food and Drug Administration granted an expanded FDA 510(k) clearance in September for Cynosure’s non-invasive body contouring product, SculpSure. This body contouring laser treatment is now cleared to treat the submental area. SculpSure has also been cleared to treat the abdomen, flanks, back, and inner and outer thighs. This treatment uses a laser to raise the temperature of body fat to disrupt and destroy fat cells, which are then naturally and permanently eliminated.

FOR MORE INFORMATION: www.SculpSure.com.